IRF4 is involved in the differentiation and maturation of B-cells, plasma cells, as well as memory T-cells, and hence, most clinical trials targeting this molecule are associated with lymphomas or plasma cell neoplasms. The gene discussed is IRF4; the disease is plasma cell neoplasm.